AI
| Followers | 843 |
| Posts | 122806 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Thursday, June 15, 2006 9:13:01 AM
IDIX GILD
Telbivudine vs Hepsera (Adefovir):
these are the 24-week phase-3b data
reported at DDW last month. (48-week
data will be reported at AASLD in Oct.)
At 24 weeks: mean log reduction in
viral load was 6.30 for Telbivudine vs
4.97 for Hepsera; % of patients PCR-
negative was 39% for Telbivudine
vs 12% for Hepsera.
Telbivudine vs Hepsera (Adefovir):
these are the 24-week phase-3b data
reported at DDW last month. (48-week
data will be reported at AASLD in Oct.)
At 24 weeks: mean log reduction in
viral load was 6.30 for Telbivudine vs
4.97 for Hepsera; % of patients PCR-
negative was 39% for Telbivudine
vs 12% for Hepsera.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
